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13069 patients per center) had CB performed. The presented long
procedure and ﬂuoroscopy exposure times (371 and 63 min,
respectively) are characteristic for very early stage in learning
curve (3) (Fig. 1). Higher rates of permanent phrenic nerve
palsy (PNP) and pulmonary vein stenosis, than reported by
others (3–6), seem to further support our opinion. Even
though, CB was superior to AAD.
6. The use of a smaller cryoballoon is associated with a higher
incidence of PNP (5). Low CB temperature early during
the freezing cycle is a sensitive warning sign of impending
PNP (7). Persistent PNP can be avoided with interruption of
CB application in case of loss of phrenic nerve capture and/or
abrupt drop in CB temperature. Data on the mode of PN
monitoring during a procedure and the minimum tempera-
ture reached in patients with permanent PNP are missing.
7. CB outcome is worse in patients with non-pulmonary AF
(5), enlarged left atrium (6) and impaired renal function (6).
The presented 1-year success rate after a single CB proce-
dure (58%) was lower than previously reported (5) and more
recently reported (3,6) by single centers. Is it only of a result
of early operators’ experience or patients’ characteristics?
Data describing patients with CB-failure would be helpful to
understand the discrepancy.
8. CB eliminates focal triggers in pulmonary veins (PV)s but
cannot be expected to reach non-PV triggers or stop/reverse
structural remodeling in persistent AF. Repeated CB is
successful only in case of AF related to PV reconnection.
Thirty-one patients had repeated CB during the blanking
period. How many of these patients had PV reconnections?
Was the time, between index and repeated procedure, long
enough for local tissue healing after index CB? Otherwise,
the repeated procedure should had been postponed in time.
We believe that, as STOP-AF trial will have potentially high
inﬂuence on future recommendations and with the introduction of
a second generation of cryoballoons (with even higher rate of PV
strictures observed [8]), the above questions need clear answers.*Maciej Wójcik, MD
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Therapy of Paroxysmal Atrial
Fibrillation in Young Patients
With Low CHADS2 Score
Worth the Risk of Periprocedural and
Long-Term Adverse Events?
To alleviate palpitations and secondary detrimental effects in patients
with atrial ﬁbrillation (AF), the interventional AF therapies have
become a kind of gold-standard in the treatment of patients with
symptomatic AF, which is why about 50,000 procedures are per-
formed each year in the United States alone. Because pulmonary vein
isolation is less effective in patients with enlarged left atria with
permanent AF, there is a trend to treat younger patients with
paroxysmal AF with only moderate atrial structural changes. None-
theless, it is well known that patients with lone AF have low annual
rates of thromboembolismand low annual rates of heart failure during
conservative follow-up. According to the CHA2DS2-VASc score
(score to predict stroke in patients with atrial ﬁbrillation), patients
with low CHADS2 score do not require oral anticoagulants because
of the more benign prognosis in lone AF (1). In the prospective,
multicenter, randomized, controlled STOP AF cryoballoon trial (A
Clinical Study of the Arctic Front Cryoablation Balloon for the
Treatment of Paroxysmal Atrial Fibrillation), Packer et al. (2)
assessed the safety and the efﬁcacy of a novel cryoballoon ablation
technology compared with AF drug therapy in 245 patients with
paroxysmal AF and a mean CHADS2 score of 0.6. Mean age of all
patients was 56 years, 77% were male, with 93% New York Heart
Association (NYHA) none/I; 163 of the patients were assigned to
cryoablation and 82 to antiarrhythmic drugs. In this study the long-
term effectiveness in the cryoablation group was reported as 69.9%
after 12 months, with a mean ﬂuoroscopy exposure time of 63 min.
Regarding the adverse events during follow-up, only 1 adverse event
(1.2%) occurred in the drug therapy arm (transfusion because of
hemorrhage) compared with 32 adverse events (14.2%) in the cry-
oablation group, not regarding the 24 patients who suffered tempo-
rary phrenic nerve palsy. Five strokes, 4 transient ischemic attacks, 2
cases of tamponades, 2 myocardial infarctions, 3 transfusions, 2
atriovenous ﬁstulas, 2 pseudoaneurysms, 4 cases of persistent phrenic
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1307nerve palsy, 7 cases of pulmonary vein stenosis > 75%, and even 1
death occurred in the cryoablation arm.Therefore, there is reasonable
doubt regarding the safety of the interventional AF procedures.
Especially in patients with lone AF it is questionable if the beneﬁt of
the AF ablation procedures in fact outweighs their risk. Further
studies are needed to assess the net-beneﬁt of these interventional
procedures. From the pulmonological point of view, serial quanti-
tative lung perfusion scans (3) and serial body plethysmography are
required in further prospective AF ablation trials to assess the long-
term effect of mild to moderate pulmonary vein stenosis and to
assess the loss of vital capacity because of phrenic nerve palsy.*Silke D. Braun, MD
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of North American STOP AF
Pivotal Trial
We appreciate very much the letters received regarding the STOP
AF trial (North American Arctic Front). This correspondence has
provided thoughtful considerations regarding ablative intervention in
general, and the cryoballoon STOPAF Trial (1) in speciﬁc. In terms
of safety issues, it is important to reiterate that we elected to include
each and every adverse event that occurred over the course of the 12
months of the trial. Although a single tamponade and infarction
episode occurred at the time of the intervention, the fatal myocardial
infarction occurred at 11 months of follow-up and was unrelated to
the ablative intervention. Of the 5 events reported as strokes, 1 was
related to the ablative intervention in a patient crossing over from
drug therapy. The other 4 events occurred at 183, 51, 30, and 260
days after ablation and were not procedure related. Such late
complications are not typically reported in other trials, but were
included in STOP AF for completeness.
Phrenic nerve injury is a signiﬁcant complication of cryoablation
occurring in 11.2%. In contrast, in the STOP AF Continued
Access Protocol (CAP AF), phrenic nerve palsy (PNP) occurred in3 procedures (3 of 85, 3.5%), with complete resolution in all 3 of
the subjects by the end of follow-up (2). This decrease in occur-
rence is in part because of the increased experience of the operators,
and therefore reﬂects early “real world” experience.
The deﬁnition of pulmonary vein (PV) stenosis, with a > 75%
reduction in cross-sectional area (approximately a 50% reduction in
diameter) used in the trial is nonstandard (3,4). The use of “area”
overestimates the severity of stenosis. A reanalysis of the STOP
AF data using a 70% diameter reduction shows that only 6 of 905
cryoablated veins (0.7%) exceeded this criterion (2). Nevertheless,
there were 2 serious stenoses during the trial, one of which required
intervention, although the other subject refused. The management
of patients with PV stenosis otherwise followed typical approaches
used in the United States and Europe (3,4). In our experience with
PV stenosis, we have found perfusion scans to be of limited value,
although they identify a decrement in perfusion in those patients
with > 65% stenosis (3). We have no experience with body-
plethysmography, nor has this been included in any prior report of
pulmonary vein stenosis or postablation phrenic nerve injury of
which we are aware. This may be an interesting topic for a later
observational study.
Based on these issues addressed in the original STOP AF
manuscript and clariﬁed here, we believe that the safety endpoints of
the trial were appropriately met and reported (1). The safety and
efﬁcacy outcomes of the STOP AF trial are also consistent with the
recent THERMOCOOL Ablation Study (5) and those from
MANTRA-PAF (Medical Antiarrhythmic Treatment or Radio-
frequency Ablation in Paroxysmal Atrial Fibrillation) (6) and
RAAFT 2 (First Line Radiofrequency Ablation versus Antiar-
rhythmic Drugs for Atrial Fibrillation: A Multicenter Randomized
Trial) (7).Additional clinical trialswill be required to establish the long-
term efﬁcacy and safety of AF ablation in patients with underlying
disease, advanced age, and more persistent AF: CABANA (Catheter
Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation
Trial) (NCT00911508); EAST (Early Treatment of Atrial
Fibrillation for Stroke Prevention) (NCT01288352); ATTEST
(Atrial Fibrillation Progression Trial) (NCT01570361).
Several questions were raised in the second letter. In this trial,
there were several patients with “early persistent AF”–deﬁned as
having undergone a single prior cardioversion–included as allowed
in the Food and Drug Administration (FDA)-approved protocol.
The letter correctly identiﬁed that 21 patients had a history of
coronary artery disease, although none had a previous myocardial
infarction.
With regard to the question about antiarrhythmic drug use, the
82 patients randomized to antiarrhythmic drug therapy were
treated with an approved AF treatment drugdpropafenone, ﬂe-
cainide, or sotaloldthat they had not previously failed. The use of
dofetilide and amiodarone were precluded by the U.S. FDA as
a condition of study approval. Had these been available, the overall
drug response rate may have been higher, although these are similar
to the outcome of drug RX in early randomized AF ablation studies
(5). There were, however, 13 cryoablated patients treated with an
antiarrhythmic drug that had been previously ineffective, without
any additional AF after the ablation, thus meeting efﬁcacy criteria
as speciﬁed by the protocol.
We agree with the impact of experience. Even in the STOP AF
Continued Access Protocol, outcomes were better after an incre-
ment in experience (2). As indicated in the current publication, the
STOP AF investigators used this approach without extensive prior
experience, although the STOP AF efﬁcacy outcome is not
